Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Advaxis, Inc. - Common Stock (OP:ADXS)

0.2500 UNCHANGED
Streaming Delayed Price Updated: 2:39 PM EST, Jan 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.2500
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.2500
Today's Range 0.2500 - 0.2500
52wk Range 0.0270 - 0.8010
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
From Ayala Pharmaceuticals
Via GlobeNewswire

Performance

YTD
+216.1%
+216.1%
1 Month
+68.8%
+68.8%
3 Month
+390.2%
+390.2%
6 Month
+650.8%
+650.8%
1 Year
+825.9%
+825.9%

More News

Read More
News headline image
Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
From Immunome, Inc.
Via Business Wire
News headline image
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Ayala Pharmaceuticals Announces AL102 Receives Orphan Drug Designation for Desmoid Tumors
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Ayala Pharmaceuticals Announces Closing of Merger with Biosight
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Ayala Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Corporate Update
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Ayala Pharmaceuticals Announces Abstracts on AL102 and AL101 Accepted for Presentation at ESMO Congress 2023
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Ayala Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA Regarding AL102 for the Treatment of Desmoid Tumors
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Updated RINGSIDE Phase 2 Results Featured in Poster Discussion Session at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 30, 2023 ↗
Via Benzinga
News headline image
Ayala Pharmaceuticals Announces Updated RINGSIDE Phase 2 Results at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Ayala Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Corporate Update
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Ayala Pharmaceuticals Announces RINGSIDE Results to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Ayala Pharmaceuticals Inc. (OTC:ADXS) Announces Continuation of RINGSIDE Phase 2/3 Study in Desmoid Tumors
Via News Direct
News headline image
Ayala Pharmaceuticals Announces Continuation of RINGSIDE Phase 2/3 Study in Desmoid Tumors Following Recommendation of Independent Data Monitoring Committee
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Ayala Pharmaceuticals Reports Financial Results For the Fiscal Year Ended October 31, 2022
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Ayala Pharmaceuticals and Advaxis Agree To Combine, Expect Uplisting On NASDAQ ↗
Via Benzinga
News headline image
Ayala Pharmaceuticals and Advaxis Enter into Merger Agreement
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
ADXS Investor Alert – Monteverde & Associates PC and Kahn Swick & Foti, LLC Obtain Material Disclosures Regarding the Upcoming Shareholder Vote for Advaxis, Inc. - ADXS
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
Via Benzinga

Frequently Asked Questions

Is Advaxis, Inc. - Common Stock publicly traded?
Yes, Advaxis, Inc. - Common Stock is publicly traded.
What exchange does Advaxis, Inc. - Common Stock trade on?
Advaxis, Inc. - Common Stock trades on the OTC Traded
What is the ticker symbol for Advaxis, Inc. - Common Stock?
The ticker symbol for Advaxis, Inc. - Common Stock is ADXS on the OTC Traded
What is the current price of Advaxis, Inc. - Common Stock?
The current price of Advaxis, Inc. - Common Stock is 0.2500
When was Advaxis, Inc. - Common Stock last traded?
The last trade of Advaxis, Inc. - Common Stock was at 01/20/26 02:39 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.